Abbreviations
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
ABI Ankle-brachial index
ACC American College of Cardiology
ACS Acute coronary syndrome
AE Adverse event
AHA American Heart Association
AIDS Acquired immune deficiency syndrome
ALT Alanine aminotransferase
AP Angina pectoris
apo B Apolipoprotein B
APOC3 Apolipoprotein C3
AST Aspartate aminotransferase
ATP Adult Treatment Panel
BMI Body mass index
BUN Blood urea nitrogen
CABG Coronary artery bypass graft
CAD Coronary artery disease
CBC Complete blood count
CEC Clinical Endpoint Committee
CHD Coronary heart disease
CHF Congestive heart failure
CI Confidence interval
CK-MB Creatine kinase-MB fraction
CrCL Creatinine clearance
CRF Case report form
CV Cardiovascular
CVD Cardiovascular disease
DHA Docosahexaenoic acid
DMC Data Monitoring Committee
EC Independent Ethics Committee
ECG Electrocardiogram
EDC Electronic data capture
eGRF Estimated glomerular filtration rate
EPA Eicosapentaenoic acid
Ethyl-EPA ethyl eicosapentaenoic acid
EU European Union
FBG Fasting blood glucose
FDA United States Food and Drug Administration
FSH Follicle-stimulating hormone
GCP Good Clinical Practice
GGT Gamma-glutamyl transferase
GMP Good Manufacturing Practice
GWAS Genome-wide association study
HbA1c Hemoglobin A1c
Hct Hematocrit
HDL-C High-density lipoprotein cholesterol
HF Heart failure
Hgb Hemoglobin
HIV Human immunodeficiency virus
HR Hazard ratio
hs-CRP High-sensitivity C-reactive protein
hsTnT High-sensitivity troponin T
HTG Hypertriglyceridemia
ICF Informed consent form
ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
IFCC International Federation of Clinical Chemistry
IMP Investigational medicinal product
IQR Interquartile range
IRB Institutional Review Board
ITT Intent-to-Treat
IWRS Interactive Web Response System
JAS Japanese Atherosclerosis Society
LBBB Left bundle branch block
LDL-C Low-density lipoprotein cholesterol
LOE Lack of efficacy
LpPLA2 Lipoprotein-associated phospholipase A2
LVH Left ventricle hypertrophy
MACE Major adverse coronary event
MI Myocardial infarction or mitral insufficiency
mITT Modified Intent-to-Treat
NCEP National Cholesterol Education Program
NGSP National Glycohemoglobin Standardization Program
NMR Nuclear magnetic resonance
NSTE-ACS Non-ST-segment elevation acute coronary syndrome
O3FA Omega-3 fatty acid
ODIS Off drug in stud y OGTT Oral glucose tolerance test
OR Odds ratio
PAD Peripheral arterial disease
PCI Percutaneous coronary intervention
PCSK9 Proprotein convertase subtilisin kexin 9
PH Proportional hazard
PI Principal Investigator
PP Per protocol
PVD Peripheral vascular disease
RBC Red blood cells
RLP-C Remnant lipoprotein cholesterol
RR Relative risk
SAE Serious adverse event
SAP Statistical Analysis Plan
SC Steering Committee
SPC Summary of Product Characteristics
SUSAR Suspected unexpected serious adverse reaction
TC Total cholesterol
TEAE Treatment-emergent adverse event
TG Triglycerides
TIA Transient Ischemic Attack
TIMI Thrombolysis In Myocardial Infarction
ULN Upper limit of normal
US United States
USPI United States Prescribing Information
VLDL-C Very low density lipoprotein cholesterol
WBC White cell blood count